Tiziana’s Phase 2 Alzheimer’s Trial Doses First Patient
Tiziana Life SciencesLife Sciences has dosed the first patient in a randomized, placebo-controlled Phase 2 study of intranasal foralumab...
A Vulnerable Infant Gut: The Critical Need for Restoration
Across multiple infant cohorts, up to 24% of U.S. infants had no detectable Bifidobacterium, with the absence rising to...
Immunovant Announces Pricing for Sizable $550M Stock Sale
Immunovant priced an underwritten public offering of 26.2 million primary shares at $21.00 per share for anticipated gross proceeds...
Cullgen’s Pain Drug CG001419 Shows Positive Phase 1 Results
Phase 1 data in 78 healthy volunteers showed CG001419 was well tolerated across single- and multiple-ascending doses with no...
Remarkable Lorundrostat Trial Noted by JAMA Research Roundup
Lorundrostat cut automated office systolic blood pressure by a mean 16.9 mmHg at Week 6 and 19.0 mmHg at...
FDA Approves Uplizna, A New Hope for Myasthenia Gravis
FDA has approved inebilizumab-cdon (Uplizna) for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive, based...
Tenaya’s Heart Gene Therapy Shows Promising Early Results
At the 3E13 vg/kg dose in Tenaya Therapeutics’ RIDGE-1 Phase 1b/2 study, three adults with PKP2-associated ARVC showed early...
First Patient Dosed in Tiziana’s Phase 2 Alzheimer’s Trial
TSPO-PET imaging in an Alzheimer’s patient already on lecanemab showed persistent, widespread microglial activation, underscoring residual neuroinflammation despite amyloid...
Parexel’s Spectacular Win: Named Best CRO at Scrip Awards
Parexel has been named Best Contract Research Organization in the full-service category at the 21st Scrip Awards, a peer-judged...
TissueCypher: A Breakthrough in Esophageal Cancer Risk ID
Across six published studies, patients flagged as high risk by Castle Biosciences’ TissueCypher Barrett’s Esophagus test were 6.7 times...